LINCOLN Stock Overview
Engages in manufacturing and trading of pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Lincoln Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹787.80 |
| 52 Week High | ₹979.50 |
| 52 Week Low | ₹534.80 |
| Beta | 0.65 |
| 1 Month Change | 24.79% |
| 3 Month Change | 13.25% |
| 1 Year Change | 21.81% |
| 3 Year Change | 116.91% |
| 5 Year Change | 296.88% |
| Change since IPO | 260.30% |
Recent News & Updates
Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified
Dec 05
Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Are Of Questionable Quality
Nov 23Recent updates
Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified
Dec 05Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Are Of Questionable Quality
Nov 23Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be Increased To ₹1.80
Sep 08Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?
Sep 06Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market
Mar 14Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Nov 04Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 14Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50
Aug 31Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 12Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50
Aug 29If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late
Feb 14Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?
Aug 16Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock
May 06Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?
Apr 03Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?
Mar 15Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?
Feb 28Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares
Feb 12Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Feb 01
Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years
Jan 19Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares
Jan 06Shareholder Returns
| LINCOLN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.8% | 2.0% | -0.3% |
| 1Y | 21.8% | 39.5% | 16.3% |
Return vs Industry: LINCOLN underperformed the Indian Pharmaceuticals industry which returned 39.5% over the past year.
Return vs Market: LINCOLN exceeded the Indian Market which returned 16.3% over the past year.
Price Volatility
| LINCOLN volatility | |
|---|---|
| LINCOLN Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: LINCOLN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: LINCOLN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,687 | Mahendrabhai Patel | www.lincolnpharma.com |
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia.
Lincoln Pharmaceuticals Limited Fundamentals Summary
| LINCOLN fundamental statistics | |
|---|---|
| Market cap | ₹15.77b |
| Earnings (TTM) | ₹966.39m |
| Revenue (TTM) | ₹5.97b |
16.3x
P/E Ratio2.6x
P/S RatioIs LINCOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LINCOLN income statement (TTM) | |
|---|---|
| Revenue | ₹5.97b |
| Cost of Revenue | ₹2.87b |
| Gross Profit | ₹3.10b |
| Other Expenses | ₹2.13b |
| Earnings | ₹966.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 48.25 |
| Gross Margin | 51.90% |
| Net Profit Margin | 16.18% |
| Debt/Equity Ratio | 0.2% |
How did LINCOLN perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 20:28 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |